AlphAIAlphAI — Financial news for AI agents
investing.com$AMRX

Amneal Pharmaceuticals earnings beat by $0.03, revenue topped estimates

Amneal Pharmaceuticals (AMRX) reported Q3 EPS of $0.26, beating estimates by $0.03, with revenue at $862.68M, exceeding expectations. The company guided FY 2026 EPS to $1.04-$1.08 and revenue to $3.15B-$3.25B. AMRX stock is up 13.12% in 3 months and 80.09% in 12 months.

Original reporting
investing.com
Published Nov 3, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMRX
Bullish
high confidence
Mentioned
$AMRX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRXBullishHigh
01

Why it matters

The earnings surprise and guidance lift sentiment, suggesting a short‑term rally, though the magnitude may be moderated by broader market conditions.

02

Market read

Earnings beat provides a clear trading catalyst for AMRX and may influence peer valuations.

03

What to watch

Potential headwinds from upcoming generic competition are not discussed.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Amneal Pharmaceuticals (NASDAQ: AMRX) released its Q3 2026 earnings, beating both EPS and revenue estimates and providing FY guidance slightly above consensus.

Company-level read

Ticker impact

$AMRXBullishHigh confidence
Context

Amneal Pharmaceuticals reported Q3 EPS of $0.260 beating estimates and revenue of $862.68M above consensus.

Expected impact

likely upward pressure as investors price in the beat and higher FY guidance

Evidence & confidence

The beat exceeds expectations and FY2026 EPS guidance is above consensus, which typically drives buying.

Market effects

Sector

Positive earnings may lift other specialty pharma peers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to U.S. and global pharma investors.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑cover pull‑back.

Key entities

  • company
    Amneal Pharmaceuticals

    Specialty pharmaceutical company reporting earnings.

Read at source← All news

StoryAmneal Pharmaceuticals raises 2026 revenue and earnings guidance after Q3 2026 results

Also covered by

5 outlets

Related articles

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

tipranks.com
$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.

investing.com
$AMRXMedAI 8/10

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Amneal Pharmaceuticals (AMRX) reported Q3 revenue growth in affordable medicines (19% to $547M) and specialty products (20% to $150M), while AvKARE revenue declined 17% to $165M. Adjusted gross margin increased to 43.2%. The company launched lanreotide, targeting 30-40% market share, and expects significant biosimilar growth. Specialty brands like CREXONT and BREKIYA showed strong performance. Amneal plans manufacturing expansions and aims to reduce leverage below 3x EBITDA by 2028.

finance.yahoo.com